-
公开(公告)号：EP1383800A1
公开(公告)日：2004-01-28
申请号：EP02757920.0
申请日：2002-04-02
发明人： REFF, Mitchell, E. , DAVIES, Julian
CPC分类号： C12N9/1051 , A61K2039/505 , C07K16/00 , C07K16/2896 , C07K2317/24 , C07K2317/41 , C07K2317/732 , C12P21/005 , Y02A50/466
摘要： Methods, compostions and kits comprising antibodies for the treatment of neoplastic, autoimmune or other disorders are provided.
-
12.发明公开
公开(公告)号：EP1370292A1
公开(公告)日：2003-12-17
申请号：EP02704280.3
申请日：2002-01-31
IPC分类号： A61K45/00 , A61K45/06 , A61K39/395 , A61P35/00 , A61P35/02
CPC分类号： C07K16/2896 , A61K47/6849 , A61K2039/505 , C07K16/2827 , C07K16/2851 , C07K16/2875 , C07K2317/24 , C07K2317/732
摘要： Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
-
13.发明公开NON-AGONISTIC ANTIBODIES TO HUMAN GP39, COMPOSITIONS CONTAINING, AND THERAPEUTIC USE THEREOF 审中-公开NICHTAGONISTISCHE抗体的人gp39的，组合物和用途
公开(公告)号：EP1299542A2
公开(公告)日：2003-04-09
申请号：EP01941911.8
申请日：2001-06-06
发明人： ANDERSON, Darrell, R. , PAN, Li, Zhen , HANNA, Nabil , RASTETTER, William, H. , KLOETZER, William, S.
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2317/24
摘要： The present invention is directed to antibodies which bind human gp39, are antagonistic of the CD40/CD40L interaction, but are non-agonistic of T-cell activation. The present invention is further directed to the use of these antibodies as therapeutic agents. These antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.
-
14.发明授权
公开(公告)号：EP0669986B1
公开(公告)日：2003-04-09
申请号：EP94901599.4
申请日：1993-11-12
发明人： REFF, Mitchell, E.
CPC分类号： C12N15/52 , C07K16/2896 , C12N15/65 , C12N15/67 , C12N15/85 , C12N2800/108 , C12N2840/20 , C12N2840/44
摘要： Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector. These vectors are most typically utilized in the expression of proteins in mammalian expression systems. As defined, disclosed and claimed herein, a "fully impaired consensus Kozak" comprises sequence (I), where: "x" is a nucleotide selected from the group consisting of adenine (A), quanine (G), cytosine (C) or thymine (T)/uracil (U); "Py" is a pyrimidine nucleotide, ie C or TU; "ATG" is a codon encoding for the amino acid methionine, the so-called "start" codon; and -3 and +1 are directional reference points vis-à-vis ATG, ie -3 is meant to indicate three nucleotides upstream of ATG and +1 is meant to indicate one nucleotide downstream of ATG. Dominant selectable markers further comprising artificial intronic insertion regions are further disclosed.
-
15.发明公开TREATMENT OF INTERMEDIATE- AND HIGH-GRADE NON-HODGKINS LYMPHOMA WITH ANTI-CD20 ANTIBODY 审中-公开非霍奇金淋巴瘤MIDDLE处理对高恶性肿瘤，抗CD20抗体
公开(公告)号：EP1227836A1
公开(公告)日：2002-08-07
申请号：EP00955249.8
申请日：2000-08-02
IPC分类号： A61K39/00 , A61K49/16 , A61K51/00 , A61K51/10 , A61M36/06 , C07K16/28 , C12P21/08 , G01N33/15 , G01N33/50 , G01N33/53
CPC分类号： C07K16/2887 , A61K31/475 , A61K31/573 , A61K31/664 , A61K31/675 , A61K31/704 , A61K35/28 , A61K35/545 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K2317/24 , Y10S424/801 , A61K2300/00
摘要： This invention discloses methods for the treatment of intermediate- and high-grade non-Hodgkins lymphomas comprising administration of anti-CD20 antibodies.
-
16.发明公开TREATMENT OF PATIENTS HAVING NON-HODGKINS LYMPHOMA WITH BONE MARROW INVOLVEMENT WITH ANTI-CD20 ANTIBODIES 审中-公开非霍奇金淋巴瘤的患者的骨髓治疗与抗CD20抗体的参与
公开(公告)号：EP1207906A1
公开(公告)日：2002-05-29
申请号：EP00965561.4
申请日：2000-07-25
IPC分类号： A61K39/395
CPC分类号： C07K16/2887 , A61K39/39558 , A61K2039/505 , C07K2317/24 , A61K2300/00
摘要： This invention relates to methods of reducing bone marrow involvement in B cell lymphoma patients prior to radioimmunotherapy by administering monoclonal antibodies which target cancerous B cells.
-
公开(公告)号：EP1192463A2
公开(公告)日：2002-04-03
申请号：EP00913645.8
申请日：2000-02-29
IPC分类号： G01N33/534 , G01N33/60
CPC分类号： G01N33/534 , G01N33/60
摘要： Antibody binding assays and radiolabeling kits are disclosed for radiolabeling and testing therapeutic antibodies in the commercial setting. In particular, the kits are designed for making and evaluating radiolabeled anti-CD20 conjugates to be used for the treatment and imaging of B cell lymphoma tumors. All kit reagents are sterile and are designed to achieve a high level of antibody radiolabeling and product stability with results which are highly reproducible.
-
18.发明公开CHIMERIC ANTI-CD20 ANTIBODY TREATMENT OF PATIENTS RECEIVING BMT OR PBSC TRANSPLANTS 有权的患者治疗骨髓移植或移植的外周血干细胞抗CD20抗体GET
公开(公告)号：EP1131096A1
公开(公告)日：2001-09-12
申请号：EP99958649.8
申请日：1999-11-09
IPC分类号： A61K39/395 , A61K39/00 , A01N63/00 , A01N1/02 , A01N1/00
CPC分类号： C07K16/2887 , A61K39/3955 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The use of a chimeric anti-CD20 antibody, RITUXAN®, as an in vivo or in vitro purging agent, of patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related malignancies, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
-
19.发明公开TREATMENT OF HEMATOLOGIC MALIGNANCIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODY 审中-公开与循环肿瘤细胞使用嵌合抗CD20抗体相关治疗恶性血液病
公开(公告)号：EP1131093A1
公开(公告)日：2001-09-12
申请号：EP99960232.9
申请日：1999-11-09
IPC分类号： A61K39/00
CPC分类号： C07K16/2887 , A61K31/196 , A61K31/573 , A61K31/675 , A61K31/7076 , A61K38/191 , A61K38/193 , A61K38/2026 , A61K38/212 , A61K39/395 , A61K39/3955 , A61K2039/505 , C23C2/02 , C23C2/06 , C23C2/30 , A61K2300/00
摘要： A method of treating hematologic malignancies associated with a high number of circulating tumor cells by the administration of a therapeutic chimeric anti-CD20 antibody. These malignancies include in particular B-prolymphocytic leukemia (B-PLL), chronic lymphocytic leukemia (CLL), and transformed non-Hodgkin's lymphoma.
-
公开(公告)号：EP0669986A1
公开(公告)日：1995-09-06
申请号：EP94901599.0
申请日：1993-11-12
发明人： REFF, Mitchell, E.
CPC分类号： C12N15/52 , C07K16/2896 , C12N15/65 , C12N15/67 , C12N15/85 , C12N2800/108 , C12N2840/20 , C12N2840/44
摘要： Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector. These vectors are most typically utilized in the expression of proteins in mammalian expression systems. As defined, disclosed and claimed herein, a 'fully impaired consensus Kozak' comprises sequence (I), where: 'x' is a nucleotide selected from the group consisting of adenine (A), quanine (G), cytosine (C) or thymine (T)/uracil (U); 'Py' is a pyrimidine nucleotide, ie C or TU; 'ATG' is a codon encoding for the amino acid methionine, the so-called 'start' codon; and -3 and +1 are directional reference points vis-à-vis ATG, ie -3 is meant to indicate three nucleotides upstream of ATG and +1 is meant to indicate one nucleotide downstream of ATG. Dominant selectable markers further comprising artificial intronic insertion regions are further disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
57 条记录 (耗时 0.023 秒)
